NCT04747977 - To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease | Biotech Hunter

Enrollment

172

Participants

Timeline

Start Date

February 12, 2021

Primary Completion Date

August 11, 2021

Study Completion Date

September 22, 2021

Conditions

Dry Eye

Interventions

DRUG

OTX-DED

0.2mg dexamethasone ophthalmic insert

DRUG

OTX-DED

0.3mg dexamethasone ophthalmic insert

DRUG

OTX-DED

Hydrogel vehicle ophthalmic insert

Trial Locations (15)

12603

Ocular Therapeutix, Poughkeepsie

16066

Ocular Therapeutix, Inc., Cranberry Township

27603

Ocular Therapeutix, Inc., Raleigh

33484

Ocular Therapeutix, Inc., Delray Beach

33773

Ocular Therapeutix, Inc., Largo

38119

Ocular Therapeutix, Inc., Memphis

46260

Ocular Therapeutix, Inc., Indianapolis

60555

Ocular Therapeutix, Warrenville

63131

Ocular Therapeutix, Inc., St Louis

64111

Ocular Therapeutix, Kansas City

77573

Ocular Therapeutix, Inc., League City

90301

Ocular Therapeutix, Inglewood

91345

Ocular Therapeutix, Inc, Mission Hills

92663

Ocular Therapeutix, Inc., Newport Beach

92705

Ocular Therapeutix, Inc., Santa Ana